NASDAQ: SGPSpyglass Pharma Inc Stock
$27.83+1.65 (+6.3%)
Updated Feb 10, 2026
SGP Price
$27.83
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$20.16
52 Week High
$32.44
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.11
Operating Cash Flow
N/A
Beta
-8.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SGP Overview
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SGP's potential to beat the market
- SGP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SGP
RankedUnranked of 101
RankedUnranked of 101
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.67 | A | |
| $8.07 | A | |
| $88.72 | A |
Be the first to know about important SGP news, forecast changes, insider trades & much more!
SGP News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SGP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGP's short-term assets ($119.70M) exceed its short-term liabilities ($6.61M)
Short-term Liabilities Financials
SGP's short-term assets ($119.70M) exceed its long-term liabilities ($3.09M)
Long-term Liabilities Financials
SGP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more SGP due diligence checks available for Premium users.
Valuation
SGP's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$127.0M
Liabilities
$9.7M
Debt to equity
-0.11
SGP's short-term assets ($119.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGP's short-term assets ($119.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SGP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Spyglass Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.